Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial. Th
MarketBeat ·